{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:33:23Z","timestamp":1789133603860,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Secukinumab is an anti-IL-17 monoclonal antibody approved for treating psoriasis and various arthritides. A comprehensive evaluation of its safety, especially in a real-world setting, is necessary. This study aimed to describe the adverse events (AE) associated with secukinumab use using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. FAERS data files containing AE reports from 2015 to 2021 were downloaded for data mining. Primary or secondary suspect medications indicated for psoriasis were identified and analyzed. Medical dictionary for regulatory activities (MedDRA version 24.1) was used to analyze the AE terms. To detect potential safety signals of AE from secukinumab use, disproportionality analysis was used. A total of 365,590 adverse event reports were identified; of these, 44,761 reports involved the use of secukinumab. Safety signals were identified for ocular infections and gastrointestinal adverse events at the standardised MedDRA query level. Safety signals for oral candidiasis, oral herpes, conjunctivitis, eye infections, and ulcerative colitis were identified at the preferred term level. The findings of our study are consistent with those of earlier studies, such as the increased risk of infections and inflammatory bowel disease. However, our study also identified additional safety signals that need to be further evaluated.<\/jats:p>","DOI":"10.1038\/s41598-023-50013-7","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:02:40Z","timestamp":1705082560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database"],"prefix":"10.1038","volume":"14","author":[{"given":"Vishnu","family":"Eshwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"50013_CR1","unstructured":"Biological Product Definitions | FDA. https:\/\/www.fda.gov\/files\/drugs\/published\/Biological-Product-Definitions.pdf."},{"key":"50013_CR2","unstructured":"What Are \u2018Biologics\u2019 Questions and Answers | FDA. https:\/\/www.fda.gov\/about-fda\/center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers."},{"key":"50013_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","volume":"10","author":"O Boyman","year":"2014","unstructured":"Boyman, O., Comte, D. & Spertini, F. Adverse reactions to biologic agents and their medical management. Nat. Rev. Rheumatol. 10, 612\u2013627 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"50013_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.crohns.2012.06.024","volume":"7","author":"F Aubin","year":"2013","unstructured":"Aubin, F., Carbonnel, F. & Wendling, D. The complexity of adverse side-effects to biological agents. J. Crohns Colitis 7, 257\u2013262 (2013).","journal-title":"J. Crohns Colitis"},{"key":"50013_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888\u2013898 (2009).","journal-title":"N. Engl. J. Med."},{"key":"50013_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.12688\/f1000research.10862.1","volume":"6","author":"S Khader","year":"2017","unstructured":"Khader, S. & Das, S. Yin and yang of interleukin-17 in host immunity to infection. F1000Research 6, 741 (2017).","journal-title":"F1000Research"},{"key":"50013_CR7","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J. & Moots, R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: Recent advances and controversies. Ann. Rheum. Dis. 78, 1167 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"50013_CR8","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes, J. E., Yan, B. Y., Chan, T. C. & Krueger, J. G. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J. Immunol. 201, 1605\u20131613 (2018).","journal-title":"J. Immunol."},{"issue":"Suppl 1","key":"50013_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0001-7310(14)70017-1","volume":"105","author":"SJ Blake","year":"2014","unstructured":"Blake, S. J. & Teng, M. W. L. Role of IL-17 and IL-22 in autoimmunity and cancer. Actas Dermosifiliogr. 105(Suppl 1), 41\u201350 (2014).","journal-title":"Actas Dermosifiliogr."},{"key":"50013_CR10","unstructured":"Targeting IL-17 in inflammatory disease. Nature. https:\/\/www.nature.com\/collections\/vzdlng (2014)."},{"key":"50013_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/ph15111365","volume":"15","author":"V Eshwar","year":"2022","unstructured":"Eshwar, V., Kamath, A., Shastry, R., Shenoy, A. K. & Kamath, P. A review of the safety of interleukin-17A inhibitor secukinumab. Pharmaceuticals 15, 1365 (2022).","journal-title":"Pharmaceuticals"},{"key":"50013_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdv.16124","volume":"34","author":"K Reich","year":"2020","unstructured":"Reich, K., Warren, R. B., Coates, L. C. & Di Comite, G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J. Eur. Acad. Dermatol. Venereol. 34, 1161\u20131173 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"50013_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. & Shakir, S. A. W. Under-reporting of adverse drug reactions. Drug Saf. 29, 385\u2013396 (2006).","journal-title":"Drug Saf."},{"key":"50013_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M. & Grundmark, B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: Recommendations for limiting false-positive associations. Drug Saf. 43, 479\u2013487 (2020).","journal-title":"Drug Saf."},{"key":"50013_CR15","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard | FDA. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"50013_CR16","unstructured":"(secukinumab) injection, for subcutaneous use COSENTYX (2015)."},{"key":"50013_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter, A. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 80, 1029\u20131072 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"50013_CR18","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter, A. et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J. Am. Acad. Dermatol. 82, 1445\u20131486 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"50013_CR19","doi-asserted-by":"publisher","first-page":"18818","DOI":"10.1038\/s41598-021-98325-w","volume":"11","author":"A Kamath","year":"2021","unstructured":"Kamath, A., Acharya, S. D., Rao, R. R. & Ullal, S. D. Assessment of pancreatitis associated with tocilizumab use using the United States Food and Drug Administration adverse event reporting system database. Sci. Rep. 11, 18818 (2021).","journal-title":"Sci. Rep."},{"key":"50013_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc, J.-L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72, 905 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"50013_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans, S. J. W., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"50013_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/pds.1002","volume":"13","author":"P Waller","year":"2004","unstructured":"Waller, P., van Puijenbroek, E., Egberts, A. & Evans, S. The reporting odds ratio versus the proportional reporting ratio: \u2018Deuce\u2019. Pharmacoepidemiol. Drug Saf. 13, 525\u2013526 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"50013_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. Post-marketing safety concerns with secukinumab: A disproportionality analysis of the FDA adverse event reporting system. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.862508 (2022).","journal-title":"Front. Pharmacol."},{"key":"50013_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s13555-021-00675-w","volume":"12","author":"P Foley","year":"2022","unstructured":"Foley, P. et al. Effectiveness and safety of secukinumab for psoriasis in a real-world clinical setting in the Asia-Pacific and Middle East regions: Results from the REALIA study. Dermatol. Ther. 12, 511\u2013527 (2022).","journal-title":"Dermatol. Ther."},{"key":"50013_CR25","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb, A. B. et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: Update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm. Venereol. https:\/\/doi.org\/10.2340\/actadv.v102.563 (2022).","journal-title":"Acta Derm. Venereol."},{"key":"50013_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.25259\/IJDVL_496_2021","volume":"88","author":"P Sinha","year":"2022","unstructured":"Sinha, P., Dash, M., Bhatkoti, B. & Krishnan, L. P. Epithelial herpes simplex keratitis in a patient on treatment with secukinumab for psoriasis: An effect of interleukin-17 blockade?. Indian J. Dermatol. Venereol. Leprol. 88, 225\u2013227 (2022).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"50013_CR27","doi-asserted-by":"publisher","first-page":"101156","DOI":"10.1016\/j.ajoc.2021.101156","volume":"23","author":"K Wang","year":"2021","unstructured":"Wang, K., Deaner, J. D., Knapp, A., Baynes, K. & Srivastava, S. K. Bilateral infectious scleritis from histoplasma capsulatum in an immunosuppressed uveitis patient. Am. J. Ophthalmol. Case Rep. 23, 101156 (2021).","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"50013_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-219296","author":"CE Martinez","year":"2017","unstructured":"Martinez, C. E., Allen, J. B., Davidorf, F. H. & Cebulla, C. M. Case report: Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2017-219296 (2017).","journal-title":"BMJ Case Rep."},{"key":"50013_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4103\/ijmy.ijmy_226_21","volume":"11","author":"R Venkitakrishnan","year":"2022","unstructured":"Venkitakrishnan, R. et al. A successful salvage story: Uveitis with nontuberculous mycobacterial infection in a patient on secukinumab. Int. J. Mycobacteriol. 11, 126 (2022).","journal-title":"Int. J. Mycobacteriol."},{"key":"50013_CR30","doi-asserted-by":"publisher","first-page":"e14700","DOI":"10.1111\/dth.14700","volume":"34","author":"A Polat Ekinci","year":"2021","unstructured":"Polat Ekinci, A., Pehlivan, G. & G\u00f6kalp, M. O. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience. Dermatol. Ther. 34, e14700 (2021).","journal-title":"Dermatol. Ther."},{"key":"50013_CR31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14712598.2020.1779217","volume":"20","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo, M., Tofani, L., Bianchi, L. & Talamonti, M. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. Expert Opin. Biol. Ther. 20, 829\u2013830 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"50013_CR32","first-page":"e13580","volume":"33","author":"V Di Lernia","year":"2020","unstructured":"Di Lernia, V., Bombonato, C. & Motolese, A. COVID-19 in an elderly patient treated with secukinumab. Dermatol. Ther. 33, e13580 (2020).","journal-title":"Dermatol. Ther."},{"key":"50013_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14710","author":"C Mugheddu","year":"2021","unstructured":"Mugheddu, C., Sanna, S., Atzori, L. & Rongioletti, F. Safety of secukinumab treatment in COVID-19 affected psoriatic patients. Dermatol. Ther. https:\/\/doi.org\/10.1111\/dth.14710 (2021).","journal-title":"Dermatol. Ther."},{"key":"50013_CR34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaci.2020.09.021","volume":"147","author":"JG Krueger","year":"2021","unstructured":"Krueger, J. G. et al. Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. J. Allergy Clin. Immunol. 147, 1107 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"50013_CR35","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","volume":"15","author":"A Blauvelt","year":"2016","unstructured":"Blauvelt, A. Safety of secukinumab in the treatment of psoriasis. Expert Opin. Drug Saf. 15, 1413\u20131420 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"50013_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res. Ther. 21, 1\u201311 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"50013_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.rdc.2016.09.005","volume":"43","author":"PA Bryant","year":"2017","unstructured":"Bryant, P. A. & Baddley, J. W. Opportunistic infections in biological therapy, risk and prevention. Rheum. Dis. Clin. N. Am. 43, 27\u201341 (2017).","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"50013_CR38","doi-asserted-by":"publisher","first-page":"adv00648","DOI":"10.2340\/actadv.v102.175","volume":"102","author":"L Davidson","year":"2022","unstructured":"Davidson, L., Van den Reek, J. M. P. A., Van Hunsel, F., De Jong, E. M. G. J. & Kullberg, B. J. Global risk of bacterial skin infections and herpesviridae infections with ustekinumab, secukinumab, and tumour necrosis factor-alpha inhibitors: Spontaneous reports of adverse drug reactions from the World Health Organization pharmacovigilance center. Acta Derm. Venereol. 102, adv00648 (2022).","journal-title":"Acta Derm. Venereol."},{"key":"50013_CR39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bjd.20136","volume":"185","author":"M Lebwohl","year":"2021","unstructured":"Lebwohl, M. et al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br. J. Dermatol. 185, 935\u2013944 (2021).","journal-title":"Br. J. Dermatol."},{"key":"50013_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg, S., Skov, L., Egeberg, A. & Loft, N. D. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis. JAMA Dermatol. 156, 421 (2020).","journal-title":"JAMA Dermatol."},{"key":"50013_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nri2742","volume":"10","author":"W Zou","year":"2010","unstructured":"Zou, W. & Restifo, N. P. TH17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10, 248 (2010).","journal-title":"Nat. Rev. Immunol."},{"issue":"40","key":"50013_CR42","first-page":"2071","volume":"2020","author":"D Perkovic","year":"2020","unstructured":"Perkovic, D., Simac, P. & Katic, J. IgA vasculitis during secukinumab therapy. Clin. Rheumatol. 2020(40), 2071\u20132073 (2020).","journal-title":"Clin. Rheumatol."},{"key":"50013_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/00015555-3435","volume":"100","author":"C Chelli","year":"2020","unstructured":"Chelli, C. et al. Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis. Acta Derm. Venereol. 100, 1\u20132 (2020).","journal-title":"Acta Derm. Venereol."},{"key":"50013_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/omcr\/omz041","volume":"2019","author":"E Dincses","year":"2019","unstructured":"Dincses, E. et al. Secukinumab induced Beh\u00e7et\u2019s syndrome: A report of two cases. Oxf. Med. Case Rep. 2019, 239\u2013241 (2019).","journal-title":"Oxf. Med. Case Rep."},{"key":"50013_CR45","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1097\/MIB.0000000000001142","volume":"23","author":"H Shiga","year":"2017","unstructured":"Shiga, H., Fukuda, S. & Iijima, K. Interleukin-17A inhibitor\u2013induced Crohn\u2019s disease\/beh\u00e7et\u2019s disease\u2013like lesions. Inflamm. Bowel Dis. 23, E38\u2013E39 (2017).","journal-title":"Inflamm. Bowel Dis."},{"key":"50013_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/09546634.2020.1737638","volume":"33","author":"KK Wu","year":"2022","unstructured":"Wu, K. K. & Dao, H. Off-label dermatologic uses of IL-17 inhibitors. J. Dermatol. Treat. 33, 41\u201347 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"50013_CR47","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand, J. M. et al. A randomized placebo controlled trial of secukinumab on aortic vascular inflammation in moderate to severe plaque psoriasis (VIP-S). J. Investig. Dermatol. 140, 1784 (2020).","journal-title":"J. Investig. Dermatol."},{"key":"50013_CR48","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jdv.16273","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg, A., Gisondi, P., Carrascosa, J. M., Warren, R. B. & Mrowietz, U. The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J. Eur. Acad. Dermatol. Venereol. 34, 1695 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"50013_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Perez-Alvarez","year":"2013","unstructured":"Perez-Alvarez, R., P\u00e9rez-De-Lis, M. & Ramos-Casals, M. Biologics-induced autoimmune diseases. Curr. Opin. Rheumatol. 25, 56\u201364 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"50013_CR50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.therap.2019.10.003","volume":"75","author":"N Bekkali","year":"2020","unstructured":"Bekkali, N., Simon, C., Binois, R. & Est\u00e8ve, \u00c9. Urticaire s\u00e9v\u00e8re avec r\u00e9cidive compliqu\u00e9e d\u2019angi\u0153d\u00e8me sous s\u00e9cukinumab: \u00c0 propos d\u2019un cas. Therapies 75, 509\u2013511 (2020).","journal-title":"Therapies"},{"key":"50013_CR51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10787-022-00933-z","volume":"30","author":"H Azadeh","year":"2022","unstructured":"Azadeh, H., Alizadeh-Navaei, R., Rezaiemanesh, A. & Rajabinejad, M. Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: A systematic review and meta-analysis. Inflammopharmacology 30, 435\u2013451 (2022).","journal-title":"Inflammopharmacology"},{"key":"50013_CR52","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front. Immunol. 11, 2971 (2020).","journal-title":"Front. Immunol."},{"key":"50013_CR53","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","volume":"20","author":"G Caldarola","year":"2020","unstructured":"Caldarola, G. et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: A case series and review of the literature. Expert Opin. Biol. Ther. 20, 665\u2013672. https:\/\/doi.org\/10.1080\/14712598.2020.1727439 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"50013_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622317738910","volume":"9","author":"J Frieder","year":"2018","unstructured":"Frieder, J., Kivelevitch, D. & Menter, A. Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis. Ther. Adv. Chronic Dis. 9, 5 (2018).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"50013_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/187221308784543683","volume":"2","author":"M Laan","year":"2008","unstructured":"Laan, M. & Linden, A. The IL-17 family of cytokines\u2013applications in respiratory medicine and allergology. Recent Pat. Inflamm. Allergy Drug Discov. 2, 82\u201391 (2008).","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"50013_CR56","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693 (2012).","journal-title":"Gut"},{"key":"50013_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber, S. et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: A retrospective analysis of pooled data from 21 clinical trials. Ann. Rheum. Dis. 78, 473 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"50013_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/apt.15397","volume":"50","author":"A Yamada","year":"2019","unstructured":"Yamada, A. et al. Systematic review with meta-analysis: Risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment. Pharmacol. Ther. 50, 373\u2013385 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"50013_CR59","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1093\/rheumatology\/keab193","volume":"60","author":"IA Onac","year":"2021","unstructured":"Onac, I. A. et al. Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients. Rheumatol. Oxf. Engl. 60, 5233\u20135238 (2021).","journal-title":"Rheumatol. Oxf. Engl."},{"key":"50013_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/cpt.2155","volume":"110","author":"N Petitpain","year":"2021","unstructured":"Petitpain, N. et al. IL-17 inhibitors and inflammatory bowel diseases: A postmarketing study in vigibase. Clin. Pharmacol. Ther. 110, 159\u2013168 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"50013_CR61","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","volume":"79","author":"M Fauny","year":"2020","unstructured":"Fauny, M. et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann. Rheum. Dis. 79, 1132\u20131138 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"50013_CR62","unstructured":"Medical Review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125504Orig1s000MedR.pdf. (Accessed 7th November 2023) (2015)."},{"key":"50013_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13555-019-00341-2","volume":"10","author":"E Grace","year":"2020","unstructured":"Grace, E. et al. Injection site reactions in the federal adverse event reporting system (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis. Dermatol. Ther. 10, 99\u2013106 (2020).","journal-title":"Dermatol. Ther."},{"key":"50013_CR64","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng, Z., Wang, S., Wu, C. & Wang, C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front. Pharmacol. 14, 1124628 (2023).","journal-title":"Front. Pharmacol."},{"key":"50013_CR65","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bcp.15535","volume":"89","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration adverse event reporting system database. Br. J. Clin. Pharmacol. 89, 865\u2013873 (2023).","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50013-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50013-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50013-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:11:34Z","timestamp":1705083094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50013-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50013"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50013-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"28 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1222"}}